# Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

> **NCT06436144** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 93 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Gene Mutation
- Non Small Cell Lung Cancer Stage IIIB
- Non-small Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT06436144
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2029-06
- **Final completion:** 2029-12
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06436144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06436144, "Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06436144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*